As the field of biotechnology continues to evolve, so does the treatment landscape for debilitating diseases like ulcerative colitis (UC). A recent study has shed light on the promising role of second-line Janus kinase (JAK) inhibitors in managing this condition, offering hope to patients who do not respond adequately to initial treatment. The research, led […]